London, United Kingdom – Published: 10 Aug 2026 – Euronoxx Medical Group Ltd, the exclusive UK distributor of the Koning Vera Dedicated Breast CT System, today announced the next phase of its UK clinical evaluation programme following two significant milestones that strengthen the company's commitment to evidence-based innovation and collaboration with the NHS.

Earlier this year, Health Technology Wales (HTW) completed its independent appraisal of cone-beam breast computed tomography (CBBCT), providing an evidence-based assessment of the technology and identifying the clinical and economic evidence required to determine its future role within NHS breast imaging services.
More recently, Euronoxx Medical Group was selected as one of eight innovative companies to participate in the Health Innovation East Midlands Pitch Your Product MedTech 2026 programme, recognising technologies with the potential to address future healthcare challenges through innovation and collaboration.

Together, these milestones represent important progress in Euronoxx's strategy to support the responsible evaluation of dedicated breast CT technology in the United Kingdom and provide a strong platform for expanding partnerships with NHS organisations, clinicians and academic institutions.

Building the Evidence for Tomorrow's Breast Imaging

Mandeep Goma, Chief Executive Officer of Euronoxx Medical Group Ltd, said:
“Healthcare innovation succeeds only when it is supported by robust clinical evidence and strong collaboration. The independent Health Technology Wales appraisal, together with our recent selection for the Health Innovation East Midlands Pitch Your Product MedTech 2026 programme, represents significant progress in our mission to evaluate dedicated breast CT within the UK healthcare system.

Our priority is to work alongside NHS organisations, breast imaging specialists, researchers and academic partners to generate the high-quality UK clinical evidence needed to determine where this technology may provide value for patients and healthcare services. This is not about promoting immediate adoption—it is about supporting evidence-based decision-making for the future of breast imaging.”

The Koning Vera Dedicated Breast CT System is an advanced three-dimensional breast imaging technology designed to provide true volumetric imaging without conventional breast compression. The technology has been evaluated internationally, while the HTW appraisal identified the need for additional UK clinical and health economic evidence before routine NHS adoption can be considered.

Euronoxx welcomes this evidence-led approach and believes collaborative research with NHS partners is the appropriate next step.

A Journey of Continuous Progress

Over the past two years, Euronoxx Medical Group has worked closely with clinicians, regulators and innovation organisations to establish the foundations for dedicated breast CT evaluation within the UK.

Key milestones include:
• Exclusive UK distribution of the Koning Vera Dedicated Breast CT System.
• UK regulatory registration and market readiness.
• Completion of the independent Health Technology Wales appraisal process.
• Selection for the Health Innovation East Midlands Pitch Your Product MedTech 2026 programme.
• Ongoing engagement with NHS Trusts, Cancer Alliances, breast imaging specialists and academic institutions.
• Development of collaborative clinical evaluation proposals aimed at generating robust UK evidence on diagnostic performance, patient experience and healthcare outcomes.
These achievements collectively represent important steps towards generating the robust clinical evidence needed to inform future healthcare decisions.

Driving Innovation Through Global Collaboration

David Georges, President, Koning Health, said:

“The United Kingdom has long been recognised internationally for its rigorous and evidence-based approach to evaluating healthcare innovation. We welcome the progress being made through the independent Health Technology Wales appraisal and the collaborative work now being led by Euronoxx Medical Group.
Throughout the history of breast imaging, every significant advancement has achieved acceptance through robust clinical research, independent evaluation and close collaboration with clinicians. We believe dedicated breast CT should follow that same pathway.
Koning Health is proud to support Euronoxx and its NHS and academic partners as they work to generate the high-quality UK clinical evidence needed to better understand the potential role of dedicated breast CT in modern breast imaging. We look forward to supporting this important programme and contributing to the continued advancement of evidence-based innovation that ultimately benefits women, clinicians and healthcare systems around the world.”

The Next Phase

Building on these recent milestones, Euronoxx Medical Group is expanding discussions with NHS Trusts, breast radiologists, breast surgeons, universities and research organisations to establish collaborative UK clinical evaluation programmes.

Future studies are expected to evaluate:
• Diagnostic performance
• Patient experience
• Clinical workflow
• Health economic outcomes
• Comparative imaging studies
• Real-world NHS implementation
The objective is to generate high-quality UK evidence that will support future clinical guidance and informed healthcare decision-making.

As demand for breast imaging continues to increase, Euronoxx believes collaboration between clinicians, researchers, healthcare organisations and industry will be essential to ensuring that promising technologies are evaluated rigorously, transparently and responsibly.

About Euronoxx Medical Group Ltd

Euronoxx Medical Group Ltd is a UK medical technology company specialising in the introduction, regulatory support and clinical evaluation of innovative healthcare technologies. Working in partnership with NHS organisations, universities and international manufacturers, the company supports evidence generation and responsible innovation to improve patient care.

About Koning Health

Koning Health is a global medical imaging company dedicated to advancing breast imaging through innovative three-dimensional technologies. The company's flagship Koning Vera Dedicated Breast CT System has been developed to provide high-resolution, true 3D breast imaging and is used internationally in both clinical practice and research. Koning's mission is to advance breast health through innovation, scientific collaboration and evidence-based clinical development.
Media Contact
Mandeep Goma
Chief Executive Officer
Euronoxx Medical Group Ltd
[email protected] | www.euronoxxmedical.com